Abstract:Study Objectives This study aimed to establish a population pharmacokinetic (PPK) model of intravenous voriconazole (VRC) in critically ill patients with liver dysfunction and to explore the optimal dosing strategies in specific clinical scenarios for invasive fungal infections (IFIs) caused by common Aspergillus and Candida species. Design Prospective pharmacokinetics study. Setting The intensive care unit in a tertiary-care medical center. Patients A total of 297 plasma VRC concentrations from 26 critically ill patients with liver dysfunction were included in the PPK analysis. Methods Model-based simulations with therapeutic range of 2-6 mg/L as the plasma trough concentration (C-min) target and the free area under the concentration-time curve from 0 to 24 h (integral AUC(24)) divided by the minimum inhibitory concentration (MIC) (ie, integral AUC(24)/MIC) >= 25 as the effective target were performed to optimize VRC dosing regimens for Child-Pugh class A and B (CP-A/B) and Child-Pugh class C (CP-C) patients. Results A two-compartment model with first-order elimination adequately described the data. Significant covariates in the final model were body weight on both central and peripheral distribution volume and Child-Pugh class on clearance. Intravenous VRC loading dose of 5 mg/kg every 12 h (q12h) for the first day was adequate for CP-A/B and CP-C patients to attain the C-min target at 24 h. The maintenance dose regimens of 100 mg q12h or 200 mg q24h for CP-A/B patients and 50 mg q12h or 100 mg q24h for CP-C patients could obtain the probability of effective target attainment of >90% at an MIC <= 0.5 mg/L and achieve the cumulative fraction of response of >90% against C. albicans, C. parapsilosis, C. glabrata, C. krusei, A. fumigatus, and A. flavus. Additionally, the daily VRC doses could be increased by 50 mg for CP-A/B and CP-C patients at an MIC of 1 mg/L, with plasma C-min monitored closely to avoid serious adverse events. It is recommended that an appropriate alternative antifungal agent or a combination therapy could be adopted when an MIC >= 2 mg/L is reported, or when the infection is caused by C. tropicalis but the MIC value is not available. Conclusions For critically ill patients with liver dysfunction, the loading dose of intravenous VRC should be reduced to 5 mg/kg q12h. Additionally, based on the types of fungal pathogens and their susceptibility to VRC, the adjusted maintenance dose regimens with lower doses or longer dosing intervals should be considered for CP-A/B and CP-C patients.

Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis

Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold - A Retrospective Cohort Study

A Large Sample Retrospective Study on the Distinction of Voriconazole Concentration in Asian Patients from Different Clinical Departments

Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin

Population Pharmacokinetic Model‐guided Optimization of Intravenous Voriconazole Dosing Regimens in Critically Ill Patients with Liver Dysfunction

Voriconazole plasma concentration monitoring in patients

Efficacy and Safety of Voriconazole and Cyp2c19 Polymorphism for Optimised Dosage Regimens in Patients with Invasive Fungal Infections

Optimized Administration of Voriconazole and Therapeutic Drug Monitoring in Children and Adolescents: A Single-Centre Retrospective Experience from China

Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children

A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.

Possibly Appropriate Maintenance dose of Voriconazole in pediatric patients: a single center observational study

Trough Concentration of Itraconazole and Its Relationship with Efficacy and Safety: a Systematic Review and Meta-Analysis

Population Pharmacokinetics, Safety And Dosing Optimization Of Voriconazole In Patients With Liver Dysfunction: A Prospective Observational Study

Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis

Identification of Factors Influencing the Pharmacokinetics of Voriconazole and the Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients with Invasive Fungal Infections

Therapeutic Drug Monitoring of Voriconazole in Patients with End-Stage Liver Disease.

Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective study

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients